Search
for
Sort by
Research 151–180 of 1000+
- Pegylated-interferon-α<sub>2a</sub>in clinical practice: how to manage patients suffering from side effects
- Post-finasteride syndrome
- Inflammatory perifollicular fibrosis and alopecia
- Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
- Dermatologic Adverse Events from Cancer Treatments
- Management of Toxicities of Targeted Therapies
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- Skin
- Dermatologic Care of the Transplant Patient
- LUPUS ERYTHEMATOSUS AND THE SKIN
- Chapter 14 Principles of drug metabolism
- Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
- Pharmacological and Phytochemical Updates on Citrullus colocynthis & Citrullus lanata
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- The role of protein lactylation in skin diseases: from molecular mechanisms to potential therapeutics
- Real-World Safety Profile of Generic Palbociclib in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Prospective Observational Study in Iraq”
- Decoding Hyperpigmentation from Biological Mechanisms to Actives with Clinically Proven Topical Efficacy: A Narrative Review
- Sexual dimorphism of COVID-19 inspires drug repositioning and host-targeting immunotherapy for viral pneumonia
- Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
- Pharmacotherapy of alopecia areata
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Tangled Causes, Targeted Solutions: A Comprehensive Review of Alopecia.
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Cutaneous Lupus Erythematosus
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Reversible Activation of c-Myc in Skin
- The control of hair growth: An overview
- Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
- Estrogen Leads to Reversible Hair Cycle Retardation through Inducing Premature Catagen and Maintaining Telogen